Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Similar articles for PubMed (Select 24271118)

1.

Expression of Ku86 and presence of Ku86 antibody as biomarkers of hepatitis B virus related hepatocellular carcinoma.

Xu Y, Liu AJ, Gao YX, Hu MG, Zhao GD, Zhao ZM, Liu R.

Dig Dis Sci. 2014 Mar;59(3):614-22. doi: 10.1007/s10620-013-2941-1. Epub 2013 Nov 24.

PMID:
24271118
2.

[Serum anti-Ku86: a potential biomarker for early detection of hepatocellular carcinoma].

Chu L, Zhang X, Wang G, Zhou W, Du Z, Liu A, Zhao H.

Zhonghua Zhong Liu Za Zhi. 2014 Feb;36(2):123-7. Chinese.

PMID:
24796461
3.

Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma.

Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H, Mogushi K, Miyazaki M, Yokosuka O.

Biochem Biophys Res Commun. 2012 May 18;421(4):837-43. doi: 10.1016/j.bbrc.2012.04.099. Epub 2012 Apr 25.

PMID:
22554520
4.

Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma.

Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K, Eguchi K.

Cancer. 2002 May 15;94(10):2663-8.

PMID:
12173334
5.

Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.

Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, Yang X, Qian X, Zhao X.

Carcinogenesis. 2013 Mar;34(3):595-604. doi: 10.1093/carcin/bgs372. Epub 2012 Nov 27.

6.

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.

PMID:
18422961
7.

Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus.

Chen GG, Lai PB, Ho RL, Chan PK, Xu H, Wong J, Lau WY.

J Med Virol. 2004 Jun;73(2):187-94.

PMID:
15122791
8.

Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma.

Akahoshi H, Taura N, Ichikawa T, Miyaaki H, Akiyama M, Miuma S, Ozawa E, Takeshita S, Muraoka T, Matsuzaki T, Ohtani M, Isomoto H, Matsumoto T, Takeshima F, Nakao K.

Oncol Rep. 2010 May;23(5):1317-23.

PMID:
20372846
9.

Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.

Atta MM, el-Masry SA, Abdel-Hameed M, Baiomy HA, Ramadan NE.

Clin Biochem. 2008 Oct;41(14-15):1131-9. doi: 10.1016/j.clinbiochem.2008.06.006. Epub 2008 Jun 20.

PMID:
18616935
10.

Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.

Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, Yan XD, Chen J.

World J Gastroenterol. 2012 Nov 7;18(41):5897-904. doi: 10.3748/wjg.v18.i41.5897.

11.

Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma.

Noh CK, Kim SS, Kim DK, Lee HY, Cho HJ, Yoon SY, Lee GH, Hyun SA, Kim YJ, Kim HJ, Hwang JA, Ahn SJ, Shin SJ, Lee KM, Yoo BM, Cho SW, Cheong JY.

Clin Biochem. 2014 Sep;47(13-14):1257-61. doi: 10.1016/j.clinbiochem.2014.05.002. Epub 2014 May 14.

PMID:
24836184
12.

Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study.

Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U.

Jpn J Clin Oncol. 2008 Oct;38(10):683-8. doi: 10.1093/jjco/hyn082. Epub 2008 Aug 27.

13.
14.

Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma.

Wang W, Li H, Zhou Y, Jie S.

Cancer Biomark. 2013;13(5):351-7. doi: 10.3233/CBM-130370.

PMID:
24440975
15.

SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.

Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, Cong WM, Wu MC.

J Hepatol. 2013 Sep;59(3):510-7. doi: 10.1016/j.jhep.2013.04.028. Epub 2013 May 9.

PMID:
23665285
16.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
17.

Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma.

Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL.

PLoS One. 2014 Jun 13;9(6):e99959. doi: 10.1371/journal.pone.0099959. eCollection 2014.

18.

A cancer-related protein 14-3-3ΞΆ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma.

Liu M, Liu X, Ren P, Li J, Chai Y, Zheng SJ, Chen Y, Duan ZP, Li N, Zhang JY.

Tumour Biol. 2014 May;35(5):4247-56. doi: 10.1007/s13277-013-1555-8. Epub 2014 Jan 4.

19.

Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma.

Jiang C, Zhang Y, Yu HF, Yu XT, Zhou SJ, Tan YF.

Tumour Biol. 2012 Dec;33(6):2167-72. doi: 10.1007/s13277-012-0477-1. Epub 2012 Sep 1.

PMID:
22941466
20.

Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection.

Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF.

PLoS One. 2011;6(12):e28486. doi: 10.1371/journal.pone.0028486. Epub 2011 Dec 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk